Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist

Neuroscience

Volumn 169, Issue 3, 2010, Pages 1337-1346

  Picard, M ^a   Morisset, S ^b   Cloix, J F ^a   Bizot, J C ^c   Guerin, M ^a   Beneteau, V ^a   Guillaumet, G ^a   Hevor, T K ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b INSERM   (France)

^c Key Obs SA   (France)

Author keywords

8 OH DPAT; Antipsychotic; Anxiolytic; Dopamine receptor; Glycogen; Serotonin receptor

Indexed keywords

8 [4 [(6 METHOXY 2,3 DIHYDRO[1,4]DIOXINO[2,3 B]PYRIDINE 3 YLMETHYL)AMINO]BUTYL] 8 AZA SPIRO[4.5]DECANE 7,9 DIONE; ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DOPAMINE 1 RECEPTOR; JB 788; METHAMPHETAMINE; MUSCARINIC RECEPTOR; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; TRANQUILIZING ACTIVITY;

EID: 77955282388     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.05.040     Document Type: Article

References (54)

1. Azmitia E.C. Neuronal instability: implications for Rett's syndrome. Brain Dev 2001, 23(Suppl 1):S1-S10.
2. Aznavour N., Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology 2007, 52:695-707.
3. Bernard-Helary K., Ardourel M.Y., Hevor T., Cloix J.F. In vivo and in vitro glycogenic effects of methionine sulfoximine are different in two inbred strains of mice. Brain Res 2002, 929:147-155.
4. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
5. Bonhaus D.W., Bach C., DeSouza A., Salazar F.H., Matsuoka B.D., Zuppan P., Chan H.W., Eglen R.M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 1995, 115:622-628.
6. Cao B.J., Rodgers R.J. Anxiolytic-like profile of p-MPPI, a novel 5HT1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology (Berl) 1997, 129:365-371.
7. Chalmers D.T., Watson S.J. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 1991, 561:51-60.
8. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
9. Clenet F., Hascoet M., Fillion G., Galons H., Bourin M. Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 2005, 158:339-348.
10. Cosi C., Koek W. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol 2001, 433:55-62.
11. Cuisiat S., Bourdiol N., Lacharme V., Newman-Tancredi A., Colpaert F., Vacher B. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J Med Chem 2007, 50:865-876.
12. Dawson L.A., Bromidge S.M. 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. Curr Top Med Chem 2008, 8:1008-1023.
13. Dong J., de Montigny C., Blier P. Effect of acute and repeated versus sustained administration of the 5-HT1A receptor agonist ipsapirone: electrophysiological studies in the rat hippocampus and dorsal raphe. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:303-311.
14. Drago A., De Ronchi D., Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009, 3:257-274.
15. Folbergrova J. Cyclic GMP and cyclic AMP in the cerebral cortex of mice during seizures induced by 3-mercaptopropionic acid: effects of anticonvulsant agents. Neurosci Lett 1980, 16:291-296.
16. Freo U., Pietrini P., Pizzolato G., Furey-Kurkjian M., Merico A., Ruggero S., Dam M., Battistin L. Dose-dependent effects of buspirone on behavior and cerebral glucose metabolism in rats. Brain Res 1995, 677:213-220.
17. Grasby P.M., Sharp T., Allen T., Kelly P.A., Grahame-Smith D.G. Effects of the 5-HT1A partial agonists gepirone, ipsapirone and buspirone on local cerebral glucose utilization in the conscious rat. Psychopharmacology (Berl) 1992, 106:97-101.
18. Gray L., Scarr E., Dean B. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res 2006, 143:111-120.
19. Greengrass P., Bremner R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 1979, 55:323-326.
20. Hall D.A., Strange P.G. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol 1997, 121:731-736.
21. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003, 72:1665-1682.
22. Hevor T.K., Delorme P., Beauvillain J.C. Glycogen synthesis and immunocytochemical study of fructose-1,6-biphosphatase in methionine sulfoximine epileptogenic rodent brain. J Cereb Blood Flow Metab 1986, 6:292-297.
23. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 2000, 14:177-185.
24. Hoyer D., Engel G., Kalkman H.O. Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol. Eur J Pharmacol 1985, 118:1-12.
25. Hutchins D.A., Rogers K.J. Physiological and drug-induced changes in the glycogen content of mouse brain. Br J Pharmacol 1970, 39:9-25.
26. Hutchins D.A., Rogers K.J. Effect of receptor blocking drugs on the depletion of brain glycogen by amphetamine. Br J Pharmacol 1971, 43:504-513.
27. Hutchins D.A., Rogers K.J. Effect of depletion of cerebral monoamines on the concentration of glycogen and on amphetamine-induced glycogenolysis in the brain. Br J Pharmacol 1973, 48:19-29.
28. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002, 441:137-140.
29. Joseph S.S., Lynham J.A., Colledge W.H., Kaumann A.J. Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:525-532.
30. Katzman M.A. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009, 23:103-120.
31. Kumar J.S., Mann J.J. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov Today 2007, 12:748-756.
32. Lanfumey L., Hamon M. Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl Med Biol 2000, 27:429-435.
33. Lanzenberger R.R., Mitterhauser M., Spindelegger C., Wadsak W., Klein N., Mien L.K., Holik A., Attarbaschi T., Mossaheb N., Sacher J., Geiss-Granadia T., Kletter K., Kasper S., Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007, 61:1081-1089.
34. Lazareno S., Birdsall N.J. Estimation of antagonist Kb from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol Sci 1993, 14:237-239.
35. Lepicard E.M., Venault P., Perez-Diaz F., Joubert C., Berthoz A., Chapouthier G. Balance control and posture differences in the anxious BALB/cByJ mice compared to the non anxious C57BL/6J mice. Behav Brain Res 2000, 117:185-195.
36. Levin M.C., Marullo S., Muntaner O., Andersson B., Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002, 277:30429-30435.
37. Meeter M., Talamini L., Schmitt J.A., Riedel W.J. Effects of 5-HT on memory and the hippocampus: model and data. Neuropsychopharmacology 2006, 31:712-720.
38. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
39. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000, 295:853-861.
40. Morisset S., Pilon C., Tardivel-Lacombe J., Weinstein D., Rostene W., Betancur C., Sokoloff P., Schwartz J.C., Arrang J.M. Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J Pharmacol Exp Ther 2002, 300:621-628.
41. Mulheron J.G., Casanas S.J., Arthur J.M., Garnovskaya M.N., Gettys T.W., Raymond J.R. Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J Biol Chem 1994, 269:12954-12962.
42. Naiman N., Lyon R.A., Bullock A.E., Rydelek L.T., Titeler M., Glennon R.A. 2-(Alkylamino)tetralin derivatives: interaction with 5-HT1A serotonin binding sites. J Med Chem 1989, 32:253-256.
43. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V., Millan M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 1998, 355:245-256.
44. Phelps C.H. Barbiturate-induced glycogen accumulation in brain. An electron microscopic study. Brain Res 1972, 39:225-234.
45. Richards M.H. Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2 and ileal M3 receptors. Br J Pharmacol 1990, 99:753-761.
46. Sato Y., Yasui-Furukori N., Nakagami T., Saito M., Kaneko S. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:416-418.
47. Silva R.C., Brandao M.L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 2000, 65:209-216.
48. Sprouse J.S., Reynolds L.S., Braselton J.P., Rollema H., Zorn S.H. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 1999, 21:622-631.
49. Sumiyoshi T., Bubenikova-Valesova V., Horacek J., Bert B. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 2008, 25:1037-1056.
50. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., Meltzer H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007, 95:158-168.
51. Suzuki Y., Ito T. Reserpine-induced glycogen accumulation in the epithelial cells of the mouse choroid plexus. Brain Res 1974, 70:113-122.
52. Uhlen S., Wikberg J.E. Rat spinal cord alpha 2-adrenoceptors are of the alpha 2A-subtype: comparison with alpha 2A- and alpha 2B-adrenoceptors in rat spleen, cerebral cortex and kidney using 3H-RX821002 ligand binding. Pharmacol Toxicol 1991, 69:341-350.
53. Zhang J., Zhang H., Cai W., Yu L., Zhen X., Zhang A. (2009)'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity. Bioorg Med Chem 2009, 17:4873-4880.
54. Zhou Q.Y., Grandy D.K., Thambi L., Kushner J.A., Van Tol H.H., Cone R., Pribnow D., Salon J., Bunzow J.R., Civelli O. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990, 347:76-80.